- About Us
- Image Gallery
- Download Free
Published on : Wednesday, December 9, 2015
Savonix Inc.,, the developer of an evidence-based digital neuro-cognitive assessment and brain health platform, announced today the closing of $1.5 million in seed round funding. Savonix plans to use the investment to hire key talent and to launch and scale its flagship assessment product. RoundGlass Partners led the financing round with additional participation from Kickstart Seed Fund, BMNT Capital, and strategic San Francisco-based angel investors Bandel Carano and Connecticut based, Ed Glassmeyer, among others.
The Savonix platform is built on the findings of decades of research including hundreds of peer review published papers. The Savonix assessment platform evaluates core domains of cognition in just half an hour all from a smart phone or mobile device. Savonix is the only mobile evidence-based digital neuro-cognitive assessment and health platform to deliver clinical grade results and insights. Delivery of these tools stands to revolutionize a proven, but previously analog, process based on pen, paper and timed testing.
“Savonix is founded on the knowledge that evidence-based digital neuro-assessment positively impacts the lives and health of individuals and organizations,” said Dr. Mylea Charvat, CEO and Founder of Savonix. “We know these cognitive assessments work, they’ve simply been unavailable behind the walls of academia or trapped within decades old structures that are expensive, cumbersome and inaccessible. Savonix is going to liberate these tools and make evidence-based cognitive testing available and affordable to anyone.”
“It is our mission to catalyze innovation and deliver breakthrough tools to positively impact lives. We’ve just scratched the surface of digitally delivered neuro-cognitive testing and health,” said Sunny Singh, Founder of RoundGlass Partners. “Savonix is a holistic, evidence-based brain evaluation and total brain health fitness platform with the promise of providing valuable insights into Alzheimer’s disease and dementia, ADHD, anxiety, depression, and traumatic stress, among countless other applications. We believe Savonix will transform and democratize neuro-cognitive screening and assessment and we are thrilled to partner with them to bring their platform to market.”
“This is exactly the sort of meaningful brain health science and technology that can change lives and organizations for the better,” noted individual angel investor Bandel Carano. “I eagerly invested in Savonix because of the transformational impact and significance of the research which has been implemented in a mobile device delivery model and leveraging wearable sensors and Big Data science. Also the founding team possesses both exceptional expertise and passion for the company’s mission.”